Creative Biolabs leverages cutting-edge Lipopolyplex (LPP) nanotechnology to overcome mRNA delivery challenges in preclinical research. Our platform integrates lipid-polymer hybrid nanoparticles to protect mRNA, enhance cellular uptake, and enable tissue-specific targeting—all tailored to accelerate your in vitro and in vivo studies.
Creative Biolabs' Lipopolyplex (LPP) Platform provides modular nanotechnology solutions for preclinical mRNA delivery research. By integrating programmable lipid-polymer hybrids with rational design principles, we enable researchers to:
Fig.1 LPP Delivery Development Service Highlights.
Targeting Strategy Exploration:
High-Purity mRNA Preparation:
Adaptive Immune Response Analysis:
Onco-Microenvironment Mechanistic Investigation:
LNP Characterization:
Research-Grade LNP Production:
Lipid-based Vector Development
Polymer-based Vector Development
1. Photo-responsive Gene Activation Systems
Using LPPs decorated with photosensitizers (e.g., hypericin) in photochemical strategies has been shown to enable light-triggered cytosolic nucleic acid release via ROS-mediated endosomal disruption. This approach can enable spatial and temporal control of gene expression in vitro with higher transfection efficiency in hepatocellular carcinoma models compared to PEI-based vectors while reducing cytotoxicity. It can serve as a precision tool for investigating endosomal escape kinetics and stimulus-responsive delivery mechanisms.
2. Modular Vaccine Research Platforms
Mucosal administration (e.g., via airway) of LPPs modified for tissue-resident delivery can elicit sIgA and tissue-resident memory T cells (TRM) to combat respiratory infections like RSV. Delivering mRNA antigens together with immune potentiators (e.g., Mn2+) enables investigators to probe the role of cGAS-STING pathway activation and its relationship with T-cell clonal expansion in tumor models, which will serve as a standardized system for probing adaptive immunity mechanisms.
3. Advanced CNS Delivery & Gene Editing
Peptide modification of LPPs (e.g., TfR1-targeting variants) enables receptor-mediated transcytosis across in vitro blood-brain barriers to deliver gene-editing reagents (e.g., CRISPR-Cas9 RNP) to neuronal cells. On the other hand, mitochondria-targeted LPPs exploit electrochemical gradient-responsive lipids to probe heteroplasmic mutation correction mechanisms in mitochondrial diseases to advance subcellular delivery research.
4. Tumor Microenvironment Remodeling
Surface modification of LPPs (e.g., RGD peptide conjugation) to deliver a combinatorial payload (mRNA + STING agonist) to investigate dendritic cell maturation kinetics and cytotoxic T lymphocyte trafficking patterns in metastatic models, which enables immune checkpoint modulation without any therapeutic claims to focus on the crosstalk between tumor and immune system. Cationic polymers electrostatically interact with anionic nucleic acids (DNA, mRNA, siRNA) to form polyplex nanocomplexes that protect genetic materials from enzymatic degradation and improve cellular uptake. Polyplexes have higher stability and tunable surface properties compared to lipoplexes and can encapsulate stimulus-responsive materials for the controlled release inside cells.
| Application | Core Innovation | Research Value |
|---|---|---|
| Photo-controlled Delivery | Light-triggered endosomal disruption | Spatiotemporal precision for gene circuit studies |
| Mucosal Immunity Platform | TLR agonist-enhanced APC activation | Modeling natural infection immune responses |
| CNS-Targeted Editing | Receptor-mediated transcytosis optimization | BBB penetration mechanism analysis |
| Tumor Immune Modulation | Combinatorial immune potentiator co-delivery | Tumor-immune synapse deconvolution |
This study systematically evaluates mRNA lipoplexes prepared via modified ethanol injection (MEI). Screening 18 formulations with varied cationic lipids (including DC-1-16/TC-1-12), helper lipids, and PEG-Cholesterol, researchers identified DC-1-16/DOPE/PEG-Chol as optimal. This formulation demonstrated:
The MEI method proves effective for developing mRNA delivery systems with improved translational capacity.
Fig.2 mRNA biodistribution and protein expression in mice after IM injection of mRNA lipoplexes.3
Leverage 15+ years of nucleic acid nanotechnology expertise to advance your preclinical mRNA research. Our specialized LPP development platform delivers:
Creative Biolabs pioneers end-to-end lipopolyplex development services that merge advanced polymer-lipid hybridization with targeted delivery engineering. Our platform enables researchers to overcome nucleic acid delivery barriers through customizable LPP architectures optimized for specific biological challenges, whether exploring CNS-targeted gene editing tools, dissecting tumor-immune interactions via co-delivery systems, or developing stimuli-responsive vectors for spatial control of gene expression. By integrating rational design principles with AI-accelerated formulation screening, we deliver non-viral solutions with enhanced tissue tropism and reduced off-target effects, exclusively for preclinical validation.
Partner with our nucleic acid specialists to design a bespoke LPP development strategy. Share your target tissue, payload specifications, and validation requirements to receive a feasibility assessment. For technical documentation or case studies, contact our team directly for scientific consultation.
A: LPP's lipid-polymer hybrid architecture enables superior endosomal escape and non-hepatic tissue targeting, making it particularly valuable for studying immune cell transfection mechanisms and organ-specific delivery biology.
A: We implement dsRNA removal protocols, tissue-optimized UTR designs, and low-temperature formulation processes to maintain mRNA integrity and expression kinetics throughout preclinical studies.
A: Yes, our ligand-screening platforms support tailored surface functionalization and charge optimization for cell-type-specific delivery, validated through primary cell transfection and tissue distribution studies.
A: We enable Cas9 mRNA/sgRNA co-encapsulation for gene editing research in cellular and organoid models, with comprehensive off-target effect analysis guidance.
A: Standardized microfluidic synthesis and rigorous physicochemical characterization ensure reproducible nanoparticle properties suitable for longitudinal research.
A: From design to data delivery, most projects progress through formulation optimization, in vitro validation, and optional animal studies within a multi-week framework.
References
